/Press Release

Gore's Off-the-Shelf Thoracoabdominal Branch Endoprosthesis Gaining Experience Across Europe

Hospitals now readily adopting the CE-marked device for complex visceral aortic aneurysm repairs

PUTZBRUNN, MUNICH (April 21, 2026) — W. L. Gore & Associates (Gore) today announced that its GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE), the first complete, off-the-shelf endovascular solution for complex aneurysmal disease involving the visceral aorta, is gaining experience in hospitals across Europe. 

Since its CE Mark approval earlier this year, TAMBE has been increasingly adopted in routine practice by numerous European vascular centers. Dedicated training programs have been developed to help familiarize endovascular teams with the device’s unique capabilities. 

Purpose-built to address complexity in the repair of thoracoabdominal and pararenal aortic aneurysms, TAMBE offers physicians a dedicated, modular system designed to maximize treatment flexibility while minimizing aortic coverage. The TAMBE system integrates components from other Gore devices, including the GORE® EXCLUDER® Iliac Branch Endoprosthesis, GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, and GORE® EXCLUDER® AAA Endoprosthesis, building on a legacy of over 25 years of clinical experience and a track record of 450,000 patients treated worldwide.

CE marking of TAMBE represents a significant milestone, expanding our portfolio and offering a breakthrough option for complex thoracoabdominal aortic disease across EMEA.

Willy Davison / Global Aortic Business Leader

Key device attributes include: 

  • Four integrated, precannulated internal portals for the placement of bridging stent grafts into visceral arteries
  • An aortic component that can be reconstrained, providing flexibility for precise positioning 

Proven safety and effectiveness demonstrated in the TAMBE pivotal study at 30 days and through 12 months1,2

  • 100% freedom from lesion-related mortality, conversion and migration
  • 99% freedom from disabling stroke2
  • 98% freedom from paraplegia2
  • 94% freedom from target vessel instability

“At Gore, we continue to pioneer endovascular solutions for physicians and their patients,” said Willy Davison, Gore’s Global Aortic Business Leader. “CE marking of TAMBE is a milestone that will expand our treatment portfolio and provide an innovative option for complex thoracoabdominal aortic disease across the EMEA region.” 

The GORE® EXCLUDER® Device family remains one of the most extensively studied EVAR platforms globally, with more than 1,500 peer-reviewed publications. TAMBE represents the next evolution of Gore’s patient-focused innovation in minimally invasive repair.  For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU). 

Medical Products 

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 55 million medical devices implanted over the course of 50 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. goremedical.com

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With approximately 13,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $5.3 billion. gore.com

  1. Farber, Mark A. et al. 1-year Results from the Pivotal Trial of a 4-Branch Thoracoabdominal Branch Endoprosthesis. J Vasc Surg. 81(6).e236.
  2. Farber MA, Matsumura JS, Han S, et al. Early outcomes from the pivotal trial of a four-branch off-the shelf solution to treat complex abdominal and type IV thoracoabdominal aortic aneurysms. J Vasc Surg. 2024;80(5):1326-1335.e4. doi:10.1016/j.jvs.2024.05.020
IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

26AR2012-EN02 MAT-0157-2